Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case.

Abstract

A 49-year-old man underwent partial resection of the jejunum for an abdominal tumor, which was histologically confirmed to be a gastrointestinal stromal tumor (GIST). Immunohistochemistry revealed that the tumor cells were positive for c-kit, p52, and MIB-1. He underwent resection of a total of 83 recurrent tumors over the next 36 months. A computed tomography (CT) scan done a few months later showed multiple tumor recurrences. The patient was started on imatinib mesylate 400 mg/day, and 3 months later, a CT image showed an increase in tumor size but a decrease in tumor density. Subsequent CT scans showed a marked decrease in tumor size 3 months later and no evidence of tumor recurrence 9 and 12 months after the commencement of imatinib treatment. The patient remains in complete remission 31 months after the start of treatment.

• Authors: Michiya Kobayashi, Ken Okamoto, Hajime Nakatani, Takehiro Okabayashi, Tsutomu Namikawa, Kengo Ichikawa, Hiroyuki Kitagawa, Keijiro Araki
• Journal: Surgery today (Surg Today) Vol. 36 Issue 8 Pg. 727-32 ( 2006) ISSN: 0941-1291 [Print] Japan
• PMID: 16865518 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Protein Kinase Inhibitors
• Pyrimidines
• Imatinib Mesylate
• Protein-Tyrosine Kinases

Topics

• Antineoplastic Agents (therapeutic use)
• Benzamides
• Gastrointestinal Stromal Tumors (diagnostic imaging, drug therapy, surgery)
• Humans
• Imatinib Mesylate
• Male
• Middle Aged
• Piperazines (therapeutic use)
• Protein Kinase Inhibitors (therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (therapeutic use)
• Tomography, X-Ray Computed